Katrina Paumier, Ph.D

Assistant Professor of Neurology

Additional Titles

  • Deputy Director of the Dominantly Inherited Alzheimer Network (DIAN)

Related Links


  • B.S.: University Of Illinois, Champagne-Urbanan (1995)
  • PhD: University of Cincinnati (2010)
  • Postdoctoral Fellowship: Pfizer, Inc. (2013)

Research Interests

I have over ten years of experience with both cellular and rodent models of Parkinson’s disease (PD). My research has focused on understanding the role of alpha-synuclein in the pathogenesis and treatment of PD. As a postdoctoral fellow, I examined the impact of a point mutation in the alpha-synuclein gene by characterizing the temporal course of phenotypic deficits in the A53T synucleinopothy mouse model. More recently, I developed and characterized a novel, progressive alpha-synucleinopathy rat model that recapitulates the spread and progression of the human condition. Using this model, I tested several potential disease modifying therapies that target alpha-synuclein. In addition to developing animal models of PD, I have a specific interest in translational medicine and previously conducted a retrospective database-mining project in order to assess the extent in which antidepressant treatment has disease-modifying effects in a population of early Parkinson’s patients. More recently, I have begun to investigate the potential for alpha-synuclein kinetics to serve as an early biomarker for Parkinson’s disease. I am currently the Deputy Director of the Dominantly Inherited Alzheimer Network (DIAN) longitudinal study and I help direct the laboratory operations in Dr. Randall Bateman’s laboratory.


  1. Polinski NK, Manfredsson FP, Benskey MJ, Fischer DL, Kemp CJ, Steece-Collier K, Sandoval IM, Paumier KL, Sortwell CE. (2016) Impact of age and vector contruct on striatal and nigral transgene expression. Molecular Therapy-Methods & Clinical Development. Dec 7;3:16082
  2. Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, Fanning K, Farlow MR, Hassenstab J, McDade EM, Mills S, Paumier K, Quintana M, Salloway SP, Santacruz A, Schneider LS, Wang G, Xiong C; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. (2016) The DIAN-TU Next Generation Alzheimer’s prevention trial: Adaptive design and disease progression model. Alzheimer’s Dementia. 2016 Aug 29; S1552-5260
  3. Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE (2015). Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiology of Disease; Jun 17;82:185-199.
  4. Collier TJ, O’Malley J, Rademacher DJ, Stancati JA, Sisson KA, Sortwell CE, Paumier KL, Gebremedhin KG, Steece-Collier K (2015). Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration. Neurobiology of Disease, May;77:191-203.
  5. Paumier KL, Sortwell CE, Madhavan L, Terpstra B, Daley BF, Collier TJ (2015). Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system. Experimental Neurology. Apr; 266:11-21.
  6. Paumier KL, Sortwell CE, Madhavan L, Terpstra B, Celano SL, Green JJ, Imus NM, Marckini N, Daley B, Steece-Collier K, Collier TJ (2014). Chronic Amitriptyline Treatment Attenuates Nigrostriatal Degeneration and Significantly Alters Trophic Support in a Rat Model of Parkinsonism. Journal of Neuropsychopharmacology; Sep 30.
  7. Shen W, Henry AG, Paumier KL, Li L, Mou K, Dunlop J, Berger Z, Hirst WD (2014). Inhibition of glucosylceramide synthase stimulates autophagy flux in neurons. Journal of  Neurochemistry; Jun;129(5):884-94.
  8. Li, S. Nadanaciva, Z. Berger, K. Paumier, W. Shen, J. Schwartz, K. Mou, J. Dunlop, W.D. Hirst (2013). Human A53T alpha-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons. PLoS One; Dec 31;8(12):e85815
  9. Paumier KL, Gonzales C, Chen Y, Stolyar P, Lotarski S, Rizzo S, Hsu C, Roof R, Richter KEG., Berger Z, Li L, Shen W, Monaghan M, Hirst WD, Zaleska MM, Dunlop J (2013). Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson’s disease. PLoS One; Aug 1;8(8)
  10. Paumier KL,  Siderowf AD, Auinger P, Oakes D, Espay AJ, Revilla FJ and Collier TJ, for the Parkinson Study Group Genetics and Epidemiology Working Group (2012). Tricyclic antidepressants delay the need for dopaminergic therapy in Parkinson’s disease. Movement Disorders; 27(7):880-7
  11. Kordower J., Dodiya H., Kordower A., Terpstra B., Paumier K., Madhavan L., Sortwell C., Steece-Collier K., Collier T (2011). Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiology of Disease; 43(3): 552-7
  12. Anne L Spieles-Engemann, Michael M Behbehani, Timothy J Collier, Susan L Wohlgenant, Kathy Steece-Collier, Katrina Paumier, Brian F Daley, Sara Gombash, Lalitha Madhavan, George T Mandybur, Jack W Lipton, Brian T Terpstra. Stimulation of the Rat Subthalamic Nucleus is Neuroprotective Following Significant Nigral Dopamine Neuron Loss, Neurobiology of Disease; 39 (2010) 105-115
  13. Madhavan L., Daley B., Paumier K., Sortwell C., Collier T (2008). Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson’s disease, Journal of Comparative Neurology; 515(1):102-15
  14. Lipton, JW, Tolod, E, Thompson, V, Pei, L, Paumier, KL, Terpstra, BT, Lynch, K, Collier, TJ, Sortwell, CE (2008). 3,4-Methylenedioxy-N-methamphetamine (Ecstasy) Promotes the Survival of Fetal Dopamine Neurons via the Dopamine Transporter, Neuropharmacology; 55(5): 851-9.
  15. Terpstra BT, Collier TJ, Marchionini DM, Levine ND, Paumier KL, Sortwell, CE (2007). Increased cell suspension concentration augments the survival rate of grafted tyrosine hydroxylase immunoreactive neurons, Journal of Neuroscience Methods; 166(1):13-9.
  16. Paumier KL, Terpstra BT, and Collier TJ (2006).  To differentiate, or not to differentiate: an alternative approach to stem cell therapy for Parkinson’s disease (Invited Review), International Journal of Neuroprotection and Neuroregeneration; 3(1): 20-30.